Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial. Interview recorded at the 2025 American Academy of Dermatology conference in Orlando, Florida.
Topics discussed include:
- Key insights from the new analysis of the ADORING-3 clinical trial on the use of tapinarof cream, 1% in patients with atopic dermatitis.
- Long-term safety and efficacy of tapinarof cream.
- How tapinarof cream differs from existing treatment options.
- Impacts on clinical practice.
